Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.34 |
| ▸ | RELA | Q04206 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27160297 | 0.98 | EPHX2 (0.44) | EPHX2CYP4F2CYP4A11POLBGRIA1 | |
| SCHEMBL22371798 | 0.85 | EPHX2 (0.39) | EPHX2POLBALDH1A1 | |
| SCHEMBL16709224 | 0.85 | EPHX2 (0.39) | EPHX2POLBALDH1A1 | |
| SCHEMBL14311864 | 0.83 | ALDH1A1 (0.39) | EPHX2POLBALDH1A1 | |
| SCHEMBL13056658 | 0.80 | EPHX2 (0.44) | EPHX2CYP4F2CYP4A11POLBGRIA1 | |
| SCHEMBL16202245 | 0.80 | ALDH1A1 (0.50) | EPHX2CYP4F2CYP4A11POLBGRIA1 | |
| SCHEMBL13056651 | 0.80 | ALDH1A1 (0.50) | EPHX2CYP4F2CYP4A11POLBGRIA1 | |
| SCHEMBL16202244 | 0.80 | MEN1 (0.47) | EPHX2CYP4F2CYP4A11POLBALDH1A1 | |
| SCHEMBL5853948 | 0.78 | PAOX (0.45) | POLBGRIA1RELAALDH1A1TSHR | |
| SCHEMBL14865837 | 0.78 | PAOX (0.45) | POLBGRIA1RELAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240201196-A1 | NON-COVALENT HALOTAG LIGANDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2024-06-20 | — | — | US | disclosed |
| EP-4330333-A2 | NON-COVALENT HALOTAG LIGANDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229466-A2 | NON-COVALENT HALOTAG LIGANDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240201196-A1 | NON-COVALENT HALOTAG LIGANDS | HDHD5, DIMT1, METTL14 | EPHX2 2380/4885CYP4F2 2225/4885CYP4A11 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.